DAXX mutation status of embolization-treated neuroendocrine tumors predicts shorter time to hepatic progression Journal Article


Authors: Ziv, E.; Rice, S. L.; Filtes, J.; Yarmohammadi, H.; Boas, F. E.; Erinjeri, J. P.; Petre, E. N.; Brody, L. A.; Brown, K. T.; Covey, A. M.; Getrajdman, G. I.; Maybody, M.; Raj, N.; Sofocleous, C. T.; Solomon, S. B.; Reidy-Lagunes, D.
Article Title: DAXX mutation status of embolization-treated neuroendocrine tumors predicts shorter time to hepatic progression
Abstract: Purpose: To identify common gene mutations in patients with neuroendocrine liver metastases (NLM) undergoing transarterial embolization (TAE) and establish relationship between these mutations and response to TAE. Materials and Methods: Patients (n = 51; mean age 61 y; 29 men, 22 women) with NLMs who underwent TAE and had available mutation analysis were identified. Mutation status and clinical variables were recorded and evaluated in relation to hepatic progression-free survival (HPFS) (Cox proportional hazards) and time to hepatic progression (TTHP) (competing risk proportional hazards). Subgroup analysis of patients with pancreatic NLM was performed using Fisher exact test to identify correlation between mutation and event (hepatic progression or death) by 6 months. Changes in mutation status over time and across specimens in a subset of patients were recorded. Results: Technical success of TAE was 100%. Common mutations identified were MEN1 (16/51; 31%) and DAXX (13/51; 25%). Median overall survival was 48.7 months. DAXX mutation status (hazard ratio = 6.21; 95% confidence interval [CI], 2.67–14.48; P <.001) and tumor grade (hazard ratio = 3.05; 95% CI, 1.80–5.17; P <.001) were associated with shorter HPFS and TTHP on univariate and multivariate analysis. Median HPFS was 3.6 months (95% CI, 1.7–5.3) for patients with DAXX mutation compared with 8.9 months (95% CI, 6.6–11.4) for patients with DAXX wild-type status. In patients with pancreatic NLMs, DAXX mutation status was associated with hepatic progression or death by 6 months (P =.024). DAXX mutation status was concordant between primary and metastatic sites. Conclusions: DAXX mutation is common in patients with pancreatic NLMs. DAXX mutation status is associated with shorter HPFS and TTHP after TAE. © 2018 SIR
Keywords: adult; cancer survival; aged; cancer surgery; gene mutation; major clinical study; overall survival; cancer growth; follow up; gene; progression free survival; delirium; kidney failure; medical record review; retrospective study; wild type; protein p53; neuroendocrine tumor; tumor lysis syndrome; liver metastasis; cyclin dependent kinase inhibitor 1b; tuberin; octreotide; cyclin dependent kinase inhibitor 2a; atrial fibrillation; everolimus; somatostatin derivative; aspiration pneumonia; sinus bradycardia; daxx protein; retinoblastoma binding protein 2; next generation sequencing; setd2 gene; very elderly; human; male; female; priority journal; article; men1 gene; artificial embolization; continuous renal replacement therapy
Journal Title: Journal of Vascular and Interventional Radiology
Volume: 29
Issue: 11
ISSN: 1051-0443
Publisher: Elsevier Science, Inc.  
Date Published: 2018-11-01
Start Page: 1519
End Page: 1526
Language: English
DOI: 10.1016/j.jvir.2018.05.023
PUBMED: 30342802
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 3 December 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Anne Covey
    118 Covey
  2. Diane Lauren Reidy
    146 Reidy
  3. Majid Maybody
    72 Maybody
  4. Lynn Brody
    93 Brody
  5. Samuel Rice
    11 Rice
  6. Karen T Brown
    161 Brown
  7. Stephen Solomon
    266 Solomon
  8. Elena Nadia Petre
    48 Petre
  9. Nitya Prabhakar Raj
    24 Raj
  10. Franz Edward Boas
    35 Boas
  11. Etay   Ziv
    26 Ziv
  12. John Filtes
    2 Filtes